The primary health care provider orders an intramuscular injection of phytonadione (AquaMEPHYTON) for the neonate. The nurse explains to the parents this medication is used to prevent which of the following conditions?

Choice A rationale Hypoglycemia, a condition of low blood glucose (normal range 40-60 mg/dL in neonates), is not prevented by phytonadione (vitamin K). This condition is primarily related to inadequate glucose stores or production, often seen in large or small for gestational age infants or those whose mothers had diabetes. Vitamin K is essential for coagulation factor synthesis, not glucose metabolism regulation. Choice B rationale Hyperbilirubinemia, characterized by elevated serum unconjugated bilirubin (jaundice), is not prevented by routine vitamin K administration. This condition results from increased breakdown of fetal red blood cells and the neonate's immature liver function being unable to adequately conjugate and excrete bilirubin. Vitamin K does not directly influence bilirubin processing or excretion pathways. Choice C rationale Phytonadione (vitamin K) is administered to neonates to prevent Vitamin K Deficiency Bleeding (VKDB), previously known as hemorrhagic disease of the newborn. Vitamin K is crucial for the liver's synthesis of coagulation factors II, VII, IX, and X. Neonates have low vitamin K stores and insufficient gut flora to produce it, making supplementation necessary to prevent life-threatening bleeding. Choice D rationale Polycythemia is an abnormally high concentration of red blood cells (hematocrit > 65.